DNA share

Trading in the DNA share began on the pre-list of Nasdaq Helsinki (the Helsinki Stock Exchange) on 30 November 2016, and on the official list on 2 December 2016. 

Share monitor

Basic share information

Historical price lookup

Investment calculator

Share capital

DNA has one series of shares and each share entitles to one vote. DNA’s fully paid-up share capital is EUR 72,702,225.65 and the company has 132,303,500 shares. The trading code of the shares is DNA and the ISIN code is FI4000062385.

The following table summarizes the history of DNA’s share capital:

  Number of shares outstanding Number of treasury shares Total number of shares Registered
January 1, 2013 8,478,532 1,132,144 9,610,676  
December 31, 2013 8,478,532 1,132,144 9,610,676  
Directed share issue 601   601 July 11, 2014
December 31, 2014 8,479,133 1,132,144 9,611,277  
Directed share issue 605   605 January 2, 2015
Share subscription under the share based compensation plan 6,475   6,475 January 15, 2015
Transfer of treasury shares as a part of remuneration 1,657 (1,657) 0  
December 31, 2015 8,487,870 1,130,487 9,618,357  
Transer of treasury shares as a part of remuneration 520 (520) 0  
Cancellation of treasury shares   (1,129,967) (1,129,967) October 13, 2016
Subdivision of shares (split) through share issue without payment 118,837,460   118,837,460 October 27, 2016
October 27, 2016 127,325,850 0 127,325,850  
November 30, 2016 132,031,957 0 132,031,957  
December 16, 2016 (New shares subscribed for in the personnel offering were registered in the Trade Register) 132,303,500 0 132,303,500 December 16, 2016

DNA's dividend policy

The company’s Board of Directors has adopted a dividend policy according to which DNA’s target is a dividend payout ratio which is about 70 to 90 per cent of DNA’s free cash flow to equity for the financial period, depending on the factors described below.

However, the possible payment of dividend by DNA, and the amount and timing of the dividend depend on several factors, such as DNA’s capital structure, future net sales, profit, financial position, general financial and operational situation, future outlook, the ability of the company’s subsidiaries to distribute dividends or otherwise transfer assets to the company, and other factors that the Board may consider significant.

  2016 2015 2014 2013
Dividend per share, EUR 0.55 4.72 3.54 4.13
Dividend, EUR million 72,8 40 30 30
Dividend record date 24 March 2017 4 April 2016 30 March 2015 25 March 2014
Dividend payment date 7 April 2017 11 April 2016 8 April 2015 3 April 2014

Equity Analysts following DNA

The following equity analysts have regular coverage on DNA on their own initiative. The list may be incomplete. DNA is not responsible for their views.


ABG Sundal Collier

Peter Kurt Nielssen
+44 20 7905 5631


Bank of America Merrill Lynch

Sunil Patel
+44 20 7995 1923



Simon Coles
+44 203 555 4519


Danske Bank

Panu Laitinmäki
010 236 4867


Exane BNP Paribas

Kohulan Paramaguru
+44 20 3430 8546


J.P. Morgan

Roman Arbuzov 
+44 79 0749 3491


Morgan Stanley

Terence Tsui
+44 20 7425 3095



Sami Sarkamies
09 5300 5176



Kimmo Stenvall
010 252 4561



Artem Bletski
09 6162 8729

Analysts’ consensus estimates on DNA’s key figures

You are now leaving the DNA website to go to an independent third party web site showing consensus estimates. From the link below, you will be transferred to a web page which is maintained and contains information provided by Vara Research. DNA has no control over the content, quality or reliability of the linked web page. Any liability of DNA as to content, accuracy or completeness of the information is excluded.

The information on the page is based on estimates and forecasts of analysts following DNA, independently from DNA.  The information appearing on the pages does not represent the opinion, forecasts or predictions of DNA or its management.  The information is not in any case  intended to provide investment advice. DNA assumes no responsibility for your use of the content. 

Consensus estimates >>

DNA’s Initial Public Offering was arranged on 15–24 November 2016

DNA Plc listed its shares on the official list of Nasdaq Helsinki Ltd (“Helsinki Stock Exchange”).

In the IPO, shares are offered to private individuals and entities in Finland, permanent or fixed-term employees of DNA or its subsidiaries in Finland and all agency employees who work at DNA during the subscription period, the members of the Board of Directors and the CEO of DNA, and institutional investors both in Finland and internationally. 

Important dates

  • 15 November 2016 The subscription period of the IPO begins
  • 24 November 2016 The subscription period of the Public and Personnel Offering ends 
  • 29 November 2016 Press release on the final result of the IPO
  • 30 November 2016 Trading with the shares begins on the prelist of the Helsinki Stock Exchange, excluding the personnel shares
  • 2 December 2016 Trading with the shares begins on the official list of the Helsinki Stock Exchange


Press and stock exchange releases during IPO

Share repurchases

DNA's Board of Directors decided on 18 May 2017 to use the authorisation given by the Annual General Meeting held on 22 March 2017 to acquire DNA's shares and initiate a share repurchase programme. The repurchase of shares is carried out in order to fulfil obligations pertaining to the company's share-based incentive schemes. At the beginning of repurchase programme, company had no own shares.

The number of repurchased shares may not exceed 25 per cent of the average daily volume of trade in DNA's shares. The average daily volume is based on the average daily volume of the month preceding the publication of the programme, which was 18 May 2017. The company's own shares are repurchased in proportions not corresponding to the shareholders' holdings, using the company's unrestricted shareholders' equity. The shares will be purchased at the market price prevailing on the day of the repurchase on the regulated market organised by Nasdaq Helsinki Ltd.

Repurchases 2017
Programme execution During 1 June 2017 – 14 September 2017
Authorization, no of shares 2,500,500
Authorization, % of shares 1.89%
No of shares repurchased 967,897 shares
% of shares (maximum amount) 0.73% 
Money used for repurchase, EUR million 14.0
Holding of own shares, at the authorization time 0
Stock exchange release about the programme Read the release >>
Stock exchange release about the end of the programme     Read the release >>